MustGrow Biologics Corp. (TSXV: MGRO) (OTCQB: MGROF) (FSE: 0C0) was the subject of a Market One feature on BNN Bloomberg on October 29, 2026, spotlighting the company's License and Collaboration agreement with Bayer AG covering Europe, the Middle East, and Africa. The feature discusses field trial results confirming TerraMG™'s control of soil-borne diseases, its compatibility with European application equipment, and receipt of a first milestone payment from Bayer. The coverage arrives as European regulators tighten restrictions on synthetic pesticides, a backdrop that investors may be watching closely for its implications on biological crop input demand.

Key Points

  • MustGrow Biologics Corp. (TSXV: MGRO) (OTCQB: MGROF) (FSE: 0C0) is a Saskatchewan-based agriculture biotechnology company
  • A BNN Bloomberg feature examines MustGrow's License and Collaboration agreement with Bayer AG for the Europe, Middle East, and Africa region
  • The Bayer agreement is valued at approximately USD $35–40 million before royalties and manufacturing sales; a first milestone payment has been received
  • Investors may be watching how field trial results and European regulatory trends affect commercialisation progress for TerraMG™

TerraMG™ Field Trials Confirm Soil-Borne Disease Control for Bayer Partnership

The BNN Bloomberg feature outlines that field trials conducted as part of Bayer AG's nearly two-year evaluation confirmed TerraMG™'s efficacy against soil-borne diseases and demonstrated compatibility with European application equipment. These validation results were central to Bayer proceeding with its exclusive License and Collaboration agreement with MustGrow, which covers the Europe, Middle East, and Africa region. The release states that a first milestone payment has been received under the agreement, representing a tangible commercial step for MustGrow's mustard seed-derived biocontrol platform.

Bayer Agreement Value and MustGrow's Capital-Efficient Licensing Model

MustGrow pursues a licensing-focused commercialisation strategy, partnering with global crop science companies rather than building its own sales infrastructure. The Bayer agreement is valued at approximately USD $35–40 million before royalties and manufacturing sales, according to the disclosure. MustGrow's broader portfolio includes TerraMG™ soil biocontrol and TerraSante™ biofertility products, backed by approximately 110 issued and pending patents. The company did not disclose the specific value of the first milestone payment received from Bayer in this announcement.

European Regulatory Shift Toward Biologicals Provides Commercial Context

The BNN Bloomberg feature situates MustGrow's technology against tightening European regulation on synthetic pesticides and fertilisers and growing demand for biological crop inputs. The release suggests this regulatory environment may increase market receptivity to mustard-derived biocontrol solutions of the type MustGrow is commercialising through its Bayer partnership. The immediate share price impact was not clear from available public information.